

## **BARD1 R&D UPDATE**

**Perth, Australia, 4 October 2017:** Australian life sciences company BARD1 Life Sciences Limited (ASX:BD1) (**BARD1 LSL** or the **Company**) today provided the following update on its research and development (R&D) programs.

### **Ovarian Cancer Diagnostics Program**

Preparations for the planned retrospective ovarian cancer study (OC400) are underway to further evaluate the accuracy of the multianalyte BARD1 Ovarian Cancer Test for detection of ovarian cancer in 400 samples of ovarian cancer and healthy controls using the original assay method. The Company is awaiting delivery of the assay plates and ovarian cancer samples for testing. The study will use the best set of 20 peptides (analytes) identified from previous studies. BARD1 LSL developed the protocol for this study in collaboration with its diagnostic development consultants (ResearchDx) and input from its Advisory Board. The study is expected to optimise the peptides and algorithm used in the BARD1 Ovarian Cancer Test for early detection of ovarian cancer, and show the higher accuracy of the Test using the original assay method. The study is projected to complete in December 2017.

Upon successful completion of the ovarian cancer study, the Company will then outsource assay development to a contract development organisation to build a clinical-grade assay and analytically validate the BARD1 Ovarian Cancer Test for ovarian cancer using a suitable assay platform.

### **Lung Cancer Diagnostics Program**

Based on expert advice from both its Advisory Board and diagnostic development consultants, BARD1 LSL plans to reschedule and redesign its planned retrospective lung cancer study. The Company now intends to conduct this retrospective lung cancer study after it has completed the OC400 study and built a standardised BARD1 Test using a suitable commercial assay platform (see above). Rescheduling of the lung cancer study will reduce development risks and costs, saving the Company up to \$300K in planned R&D expenditure. These funds are best employed into building a standardised assay on a commercial platform that can be readily modified (with different peptides) for testing and validation across multiple cancers. A new clinical-grade BARD1 Lung Cancer Test can then be modified and validated in lung cancer samples and healthy controls to evaluate and optimise its accuracy across all lung cancer types and stages.

### **Cancer Vaccine Program**

Stage 1 of the Cancer Vaccine collaboration with the Institute for Respiratory Health (IRH) to identify high BARD1 expressing tumour cell lines for implantation in animals has been completed. Stage 2 to evaluate the *in vivo* effectiveness of the BARD1 vaccine formulations for reducing tumour growth in animal studies will commence upon Animal Ethics Committee approval which is expected in October 2017.

- ENDS -

### **FOR MORE INFORMATION PLEASE CONTACT:**

**Peter Gunzburg**  
Chairman  
E [peter@bard1.com](mailto:peter@bard1.com)

**Dr Leearne Hinch**  
CEO  
E [leearne@bard1.com](mailto:leearne@bard1.com)  
M +61 400 414 416

**ABOUT BARD1 LIFE SCIENCES LTD (BARD1 LSL)**

BARD1 Life Sciences Ltd (ASX:BD1) is an Australian biotechnology company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. Its lead product, the BARD1 Lung Cancer Test, is a blood test in development for early detection of lung cancer, utilising novel tumour markers and a proprietary algorithm. The company's pipeline also includes the BARD1 Ovarian Cancer Test in development for early detection of ovarian cancer, and high-value diagnostic and therapeutic projects at research-stage for multiple cancers. BARD1 LSL is committed to transforming the early detection and prevention of cancer to help improve patients' lives.